Cortexyme (CRTX) Competitors $1.02 +0.07 (+7.45%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, FATE, ALEC, ACOG, CHRS, VIGL, CGEN, and PLXShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Fate Therapeutics (FATE), Alector (ALEC), Alpha Cognition (ACOG), Coherus BioSciences (CHRS), Vigil Neuroscience (VIGL), Compugen (CGEN), and Protalix BioTherapeutics (PLX). Cortexyme vs. Omnicell HealthStream Veradigm Fate Therapeutics Alector Alpha Cognition Coherus BioSciences Vigil Neuroscience Compugen Protalix BioTherapeutics Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Which has better earnings and valuation, OMCL or CRTX? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmnicell$1.14B1.13$12.53M$0.4659.43CortexymeN/AN/A-$89.94M-$2.97-0.34 Does the media refer more to OMCL or CRTX? In the previous week, Omnicell had 10 more articles in the media than Cortexyme. MarketBeat recorded 10 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 1.13 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the media. Company Overall Sentiment Omnicell Positive Cortexyme Neutral Does the MarketBeat Community believe in OMCL or CRTX? Omnicell received 352 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.75% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformOmnicellOutperform Votes50666.75% Underperform Votes25233.25% CortexymeOutperform Votes15464.44% Underperform Votes8535.56% Do institutionals & insiders have more ownership in OMCL or CRTX? 97.7% of Omnicell shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 2.5% of Omnicell shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is OMCL or CRTX more profitable? Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets Omnicell1.13% 3.82% 2.07% Cortexyme N/A -70.96%-63.53% Do analysts prefer OMCL or CRTX? Omnicell presently has a consensus price target of $46.50, indicating a potential upside of 70.08%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, OMCL or CRTX? Omnicell has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. SummaryOmnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.75M$2.92B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.3430.5026.5819.71Price / SalesN/A400.42391.69116.98Price / CashN/A168.6838.2534.62Price / Book0.263.286.794.50Net Income-$89.94M-$72.17M$3.23B$248.18M7 Day Performance7.37%4.26%4.03%1.14%1 Month Performance2.98%7.60%12.50%15.19%1 Year Performance18.60%-28.16%16.73%6.55% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.02+7.4%N/A+5.5%$30.75MN/A-0.3455Gap DownOMCLOmnicell2.4992 of 5 stars$27.46+6.5%$45.83+66.9%-6.3%$1.29B$1.14B101.713,800Positive NewsAnalyst UpgradeHSTMHealthStream4.542 of 5 stars$27.45-1.4%$32.00+16.6%+4.2%$837.91M$292.37M42.231,140Analyst RevisionHigh Trading VolumeMDRXVeradigm2.2866 of 5 stars$4.20-2.3%$14.00+233.3%-43.2%$454.71M$1.53B0.008,000News CoverageAnalyst ForecastGap DownFATEFate Therapeutics4.3788 of 5 stars$1.07+2.9%$4.60+329.9%-68.0%$122.63M$13.63M-0.65550Gap DownALECAlector3.7901 of 5 stars$1.20+2.6%$4.00+233.3%-74.7%$119.99M$88.34M-0.71270Gap DownACOGAlpha Cognition1.6757 of 5 stars$7.45+0.3%$20.00+168.5%N/A$119.35MN/A-2.91N/AEarnings ReportCHRSCoherus BioSciences3.7165 of 5 stars$1.02+5.3%$4.68+359.2%-60.8%$118.24M$266.96M-12.75330News CoverageAnalyst DowngradeVIGLVigil Neuroscience3.7214 of 5 stars$2.53+4.5%$16.25+542.3%-28.9%$118.08MN/A-1.2340Positive NewsTrading HaltedCGENCompugen1.6041 of 5 stars$1.32+4.8%$4.00+203.0%-19.0%$117.79M$27.86M66.0070News CoverageEarnings ReportAnalyst RevisionPLXProtalix BioTherapeutics2.193 of 5 stars$1.46-15.1%$15.00+927.4%+43.3%$116.10M$53.40M-11.23200High Trading Volume Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Fate Therapeutics Alternatives Alector Alternatives Alpha Cognition Alternatives Coherus BioSciences Alternatives Vigil Neuroscience Alternatives Compugen Alternatives Protalix BioTherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
